Pharma major Dr Reddys Laboratories has received US Food and Drug Administration (FDA) approval for Azacitidine Injection 100 mg/vial, a bioequivalent generic version of VIDAZA (azacitidine for injection) on September 16, 2013. The launch of product in the market is planned in the near-term.
The VIDAZA brand had U.S. sales of approximately $378.5 Million for the most recent twelve months ending July 2013 according to IMS Health.
Dr Reddy's Azacitidine for Injection 100 mg/vial is available in single use-vials.
